Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer.
Huang D, Chowdhury S, Wang H, Savage SR, Ivey RG, Kennedy JJ, Whiteaker JR, Lin C, Hou X, Oberg AL, Larson MC, Eskandari N, Delisi DA, Gentile S, Huntoon CJ, Voytovich UJ, Shire ZJ, Yu Q, Gygi SP, Hoofnagle AN, Herbert ZT, Lorentzen TD, Calinawan A, Karnitz LM, Weroha SJ, Kaufmann SH, Zhang B, Wang P, Birrer MJ, Paulovich AG. Huang D, et al. Among authors: oberg al. Cell Rep Med. 2021 Dec 21;2(12):100471. doi: 10.1016/j.xcrm.2021.100471. eCollection 2021 Dec 21. Cell Rep Med. 2021. PMID: 35028612 Free PMC article.
Folate receptor alpha as a tumor target in epithelial ovarian cancer.
Kalli KR, Oberg AL, Keeney GL, Christianson TJ, Low PS, Knutson KL, Hartmann LC. Kalli KR, et al. Among authors: oberg al. Gynecol Oncol. 2008 Mar;108(3):619-26. doi: 10.1016/j.ygyno.2007.11.020. Epub 2008 Jan 28. Gynecol Oncol. 2008. PMID: 18222534 Free PMC article.
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.
Weroha SJ, Oberg AL, Ziegler KL, Dakhilm SR, Rowland KM, Hartmann LC, Moore DF Jr, Keeney GL, Peethambaram PP, Haluska P. Weroha SJ, et al. Among authors: oberg al. Gynecol Oncol. 2011 Jul;122(1):116-20. doi: 10.1016/j.ygyno.2011.03.030. Epub 2011 Apr 22. Gynecol Oncol. 2011. PMID: 21514634 Free PMC article. Clinical Trial.
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma.
Hendrickson AE, Oberg AL, Glaser G, Camoriano JK, Peethambaram PP, Colon-Otero G, Erlichman C, Ivy SP, Kaufmann SH, Karnitz LM, Haluska P. Hendrickson AE, et al. Among authors: oberg al. Gynecol Oncol. 2012 Feb;124(2):210-5. doi: 10.1016/j.ygyno.2011.10.002. Epub 2011 Nov 1. Gynecol Oncol. 2012. PMID: 22047770 Free PMC article. Clinical Trial.
APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma.
Leonard B, Hart SN, Burns MB, Carpenter MA, Temiz NA, Rathore A, Vogel RI, Nikas JB, Law EK, Brown WL, Li Y, Zhang Y, Maurer MJ, Oberg AL, Cunningham JM, Shridhar V, Bell DA, April C, Bentley D, Bibikova M, Cheetham RK, Fan JB, Grocock R, Humphray S, Kingsbury Z, Peden J, Chien J, Swisher EM, Hartmann LC, Kalli KR, Goode EL, Sicotte H, Kaufmann SH, Harris RS. Leonard B, et al. Among authors: oberg al. Cancer Res. 2013 Dec 15;73(24):7222-31. doi: 10.1158/0008-5472.CAN-13-1753. Epub 2013 Oct 23. Cancer Res. 2013. PMID: 24154874 Free PMC article.
Tumorgrafts as in vivo surrogates for women with ovarian cancer.
Weroha SJ, Becker MA, Enderica-Gonzalez S, Harrington SC, Oberg AL, Maurer MJ, Perkins SE, AlHilli M, Butler KA, McKinstry S, Fink S, Jenkins RB, Hou X, Kalli KR, Goodman KM, Sarkaria JN, Karlan BY, Kumar A, Kaufmann SH, Hartmann LC, Haluska P. Weroha SJ, et al. Among authors: oberg al. Clin Cancer Res. 2014 Mar 1;20(5):1288-97. doi: 10.1158/1078-0432.CCR-13-2611. Epub 2014 Jan 7. Clin Cancer Res. 2014. PMID: 24398046 Free PMC article.
TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer.
Chien J, Sicotte H, Fan JB, Humphray S, Cunningham JM, Kalli KR, Oberg AL, Hart SN, Li Y, Davila JI, Baheti S, Wang C, Dietmann S, Atkinson EJ, Asmann YW, Bell DA, Ota T, Tarabishy Y, Kuang R, Bibikova M, Cheetham RK, Grocock RJ, Swisher EM, Peden J, Bentley D, Kocher JP, Kaufmann SH, Hartmann LC, Shridhar V, Goode EL. Chien J, et al. Among authors: oberg al. Nucleic Acids Res. 2015 Aug 18;43(14):6945-58. doi: 10.1093/nar/gkv111. Epub 2015 Apr 27. Nucleic Acids Res. 2015. PMID: 25916844 Free PMC article.
APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma.
Leonard B, Starrett GJ, Maurer MJ, Oberg AL, Van Bockstal M, Van Dorpe J, De Wever O, Helleman J, Sieuwerts AM, Berns EM, Martens JW, Anderson BD, Brown WL, Kalli KR, Kaufmann SH, Harris RS. Leonard B, et al. Among authors: oberg al. Clin Cancer Res. 2016 Sep 15;22(18):4746-55. doi: 10.1158/1078-0432.CCR-15-2910. Epub 2016 Mar 25. Clin Cancer Res. 2016. PMID: 27016308 Free PMC article.
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.
AlHilli MM, Becker MA, Weroha SJ, Flatten KS, Hurley RM, Harrell MI, Oberg AL, Maurer MJ, Hawthorne KM, Hou X, Harrington SC, McKinstry S, Meng XW, Wilcoxen KM, Kalli KR, Swisher EM, Kaufmann SH, Haluska P. AlHilli MM, et al. Among authors: oberg al. Gynecol Oncol. 2016 Nov;143(2):379-388. doi: 10.1016/j.ygyno.2016.08.328. Epub 2016 Sep 8. Gynecol Oncol. 2016. PMID: 27614696 Free PMC article.
206 results